Emerging drug therapies in Huntington's disease

Expert Opinion on Emerging Drugs

Volumn 14, Issue 2, 2009, Pages 273-297

  Mason, Sarah L ^a   Barker, Roger A ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Cell based therapies; Cognitive; Dopamine; Environmental influences; GABA; Glutamate; Huntington's disease; Motor; Neuroprotective; Neuropsychiatric; Pharmacology

Indexed keywords

ACR 16; AMANTADINE; AMISULPRIDE; ANTINEOPLASTIC ANTIBIOTIC; APOMORPHINE; BACLOFEN; BN 82451; BUTYRIC ACID; CANNABINOID; CLONAZEPAM; DIAZEPAM; DONEPEZIL; FLUOXETINE; HALOPERIDOL; ICOSAPENTAENOIC ACID ETHYL ESTER; KETAMINE; MEMANTINE; METHENAMINE; MILACEMIDE; MINOCYCLINE; MIRTAZAPINE; MITHRAMYCIN A; MONOAMINE OXIDASE INHIBITOR; N (7 HYDROXY 2,2,4,6 TETRAMETHYL 1 INDANYL) 4 (3 METHOXYPHENYL) 1 PIPERAZINEACETAMIDE; OLANZAPINE; QUETIAPINE; RAPAMYCIN; RISPERIDONE; RIVASTIGMINE; SULPIRIDE; TETRABENAZINE; TREHALOSE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGGRESSION; AGITATION; AKATHISIA; ALZHEIMER DISEASE; ANXIETY DISORDER; APATHY; APPETITE; CELL TRANSPLANTATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; DYSPHORIA; DYSTONIA; ELECTROLYTE DISTURBANCE; ENVIRONMENTAL FACTOR; FATIGUE; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; HUNTINGTON CHOREA; HYPERPIGMENTATION; HYPERTENSION; INSOMNIA; IRRITABILITY; MENTAL DETERIORATION; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NAUSEA; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PATHOLOGY; PSYCHOSIS; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TARDIVE DYSKINESIA; TRANSGENIC MOUSE; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; COGNITION; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; ENVIRONMENT; EXCITATORY AMINO ACID ANTAGONISTS; FETAL TISSUE TRANSPLANTATION; GABA AGONISTS; HUMANS; HUNTINGTON DISEASE; MICE; PSYCHOTIC DISORDERS;

EID: 67649304952     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210902918299     Document Type: Review

References (200)

1. Bates G, Harper P, Jones L. Huntington's disease. ed 3rd, Oxford, New York Oxford University Press (UK); 2002
2. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72:971-983 (Pubitemid 23110238)
3. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57:369-384 (Pubitemid 28237321)
4. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008;131:1057-1068
5. Aylward EH, Codori AM, Barta PE, et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996;53:1293-1296 (Pubitemid 26425076)
6. Halliday GM, McRitchie DA, Macdonald V, et al. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol 1998;154:663-672 (Pubitemid 29044235)
7. Spargo E, Everall IP, Lantos PL. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 1993;56:487-491 (Pubitemid 23171778)
8. Heinsen H, Rub U, Bauer M, et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol 1999;97:613-622 (Pubitemid 29231679)
9. Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008;27:2803-2820 (Pubitemid 351832229)
10. Leegwater-Kim J, Cha JH. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. NeuroRx 2004;1:128-138 (Pubitemid 46589346)
11. Martin JB, Gusella JF. Huntington's disease. Pathogenesis and management. N Engl J Med 1986;315:1267-1276 (Pubitemid 17049686)
12. Ikonen E, Ignatius J, Norio R, et al. Huntington disease in Finland: a molecular and genealogical study. Hum Genet 1992;89:275-280
13. Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci USA 2004;101:3498-3503 (Pubitemid 38338224)
14. Tibben A. Predictive testing for Huntington's disease. Brain Res Bull 2007;72:165-171 (Pubitemid 46367464)
15. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008;23:1491-1504
16. Kenney C, Powell S, Jankovic J. Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord 2007;22:127-130 (Pubitemid 46382686)
17. Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993;4:398-403 (Pubitemid 23231490)
18. Rubinsztein DC, Leggo J, Chiano M, et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci USA 1997;94:3872-3876 (Pubitemid 27180465)
19. Diguet E, Fernagut PO, Normand E, et al. Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history. Neurobiol Dis 2004;15:667-675 (Pubitemid 38429981)
20. MacDonald ME, Vonsattel JP, Shrinidhi J, et al. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 1999;53:1330-1332 (Pubitemid 29480096)
21. Paschen W, Hedreen JC, Ross CA. RNA editing of the glutamate receptor subunits GluR2 and GluR6 in human brain tissue. J Neurochem 1994;63:1596-1602 (Pubitemid 24326199)
22. Imarisio S, Carmichael J, Korolchuk V, et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 2008;412:191-209 (Pubitemid 351758226)
23. Kremer B. Clinical neurology of Huntington's disease. In: Bates GP, Harper P, Jones L, editors, Huntington's Disease. Oxford Monographs On Medical Genetics. Oxford: New York Oxford University Press (UK); 2002, volume 1
24. Morton AJ, Wood NI, Hastings MH, et al. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci 2005;25:157-163 (Pubitemid 40110776)
25. Goodman AO, Murgatroyd PR, Medina-Gomez G, et al. The metabolic profile of early Huntington's disease - a combined human and transgenic mouse study. Exp Neurol 2008;210:691-698
26. Ho AK, Sahakian BJ, Brown RG, et al. Profile of cognitive progression in early Huntington's disease. Neurology 2003;61:1702-1706 (Pubitemid 38020815)
27. Solomon AC, Stout JC, Weaver M, et al. Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. Mov Disord 2008;23:1830-1836
28. van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 2007;19:441-448 (Pubitemid 350156103)
29. Schoenfeld M, Myers RH, Cupples LA, et al. Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry 1984;47:1283-1287 (Pubitemid 15178748)
30. Zappacosta B, Monza D, Meoni C, et al. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease. Arch Neurol 1996;53:493-497 (Pubitemid 26177127)
31. Clelland CD, Barker RA, Watts C. Cell therapy in Huntington disease. Neurosurg Focus 2008;24:E9
32. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 1996;11:136-142 (Pubitemid 26082779)
33. Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol 2007;7:360-373 (Pubitemid 350237712)
34. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63:883-890 (Pubitemid 43882298)
35. Lawrence AD, Hodges JR, Rosser AE, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998;121(Pt 7):1329-1341 (Pubitemid 28327409)
36. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008;5:181-197
37. Priller J, Ecker D, Landwehrmeyer B, Craufurd D. A Europe-wide assessment of current medication choices in Huntington's disease. Mov Disord 2008;23:1788
38. Medivation I. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease. In, Huntington's Stud Group Website, 2008
39. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 2008;21:497-503
40. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109-120
41. Grohmann R, Koch R, Schmidt LG. Extrapyramidal symptoms in neuroleptic recipients. Agents Actions Suppl 1990;29:71-82
42. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24 (Pubitemid 46148428)
43. Koller WC, Trimble J. The gait abnormality of Huntington's disease. Neurology 1985;35:1450-1454 (Pubitemid 15242419)
44. Gimenez-Roldan S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia 1989;4:282-287 (Pubitemid 19278289)
45. Barr AN, Fischer JH, Koller WC, et al. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988;38:84-88 (Pubitemid 18028098)
46. Saran BM, Klein MS, Benay EM. Clinical evaluation of amantadine and haloperidol in Huntington's chorea. J Clin Psychiatry 1980;41:221
47. Leonard DP, Kidson MA, Brown JG, et al. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust NZ J Psychiatry 1975;9:115-118
48. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984;47:844-847 (Pubitemid 14059377)
49. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006;12:2701-2720
50. Squitieri F, Cannella M, Piorcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:69-72 (Pubitemid 32179139)
51. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002;105:441-444 (Pubitemid 34620570)
52. Bonelli RM, Niederwieser G, Tribl GG, Koltringer P. High-dose olanzapine in Huntington's disease. Int Clin Psychopharmacol 2002;17:91-93 (Pubitemid 34170774)
53. Grove VE Jr, Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med 2000;343:973-974 (Pubitemid 30727816)
54. Benazzi F. Rapid onset of tardive dyskinesia in Huntington disease with olanzapine. J Clin Psychopharmacol 2002;22:438-439 (Pubitemid 34810339)
55. Albanese A, Cassetta E, Carretta D, et al. Acute challenge with apomorphine in Huntington's disease: a double-blind study. Clin Neuropharmacol 1995;18:427-434
56. Corsini GU, Onali P, Masala C, et al. Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor. Arch Neurol 1978;35:27-30 (Pubitemid 8267695)
57. Vitale C, Marconi S, Di Maio L, et al. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: a double blind, randomized cross-over trial. Mov Disord 2007;22:2359-2364 (Pubitemid 351155981)
58. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry 1998;65:577-579 (Pubitemid 28438897)
59. Jongen PJ, Renier WO, Gabreels FJ. Seven cases of Huntington's disease in childhood and levodopa induced improvement in the hypokinetic-rigid form. Clin Neurol Neurosurg 1980;82:251-261 (Pubitemid 11100926)
60. Low PA, Allsop JL, Halmagyi GM. Huntington's chorea: the rigid form (Westphal variant) treated with levodopa. Med J Aust 1974;1:393-394
61. Reuter I, Hu MT, Andrews TC, et al. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry 2000;68:238-241 (Pubitemid 30245854)
62. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-394 (Pubitemid 18083674)
63. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372 (Pubitemid 43739938)
64. Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008;31:127-133 (Pubitemid 351787108)
65. Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24:126-129
66. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362 (Pubitemid 27087603)
67. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22:193-197 (Pubitemid 46374760)
68. Fasano A, Cadeddu F, Guidubaldi A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008;31:313-318
69. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41-47 (Pubitemid 12209517)
70. Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P. Tetrabenazine. Nat Rev Drug Discov 2009;8:17-18
71. Levine MS, Klapstein GJ, Koppel A, et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 1999;58:515-532 (Pubitemid 29530435)
72. Cepeda C, Hurst RS, Altemus KL, et al. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 2001;85:659-670 (Pubitemid 32147768)
73. Verhagen Metman L, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002;59:694-699
74. O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003;60:996-998 (Pubitemid 36858360)
75. Stewart JT. Adverse behavioral effects of amantadine therapy in Huntington's disease. South Med J 1987;80:1324-1325 (Pubitemid 17160804)
76. Beister A, Kraus P, Kuhn W, et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl 2004;68:117-122 (Pubitemid 39215445)
77. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord 2007;13:453-454 (Pubitemid 47446371)
78. Giuffra ME, Mouradian MM, Chase TN. Glutamatergic therapy of Huntington's chorea. Clin Neuropharmacol 1992;15:148-151
79. Murman DL, Giordani B, Mellow AM, et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 1997;49:153-161 (Pubitemid 27328696)
80. Shoulson I, Goldblatt D, Charlton M, Joynt RJ. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann Neurol 1978;4:279-284 (Pubitemid 8389826)
81. Perry TL, Wright JM, Hansen S, et al. Failure of aminooxyacetic acid therapy in Huntington disease. Neurology 1980;30:772-775 (Pubitemid 10033677)
82. Manyam BV, Ferraro TN, Hare TA. Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease. Brain Res 1987;408:125-130 (Pubitemid 17068422)
83. Anden NE, Dalen P, Johansson B. Baclofen and lithium in Huntington's chorea. Lancet 1973;2:93
84. Paulson GW. Lioresal in Huntington's disease. Dis Nerv Syst 1976;37:465-467
85. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989;25:252-259 (Pubitemid 19085516)
86. Yohrling G, Cha JH. Neurochemistry of Huntington's disease. In: Bates GP, Harper P, Jones L, editors, Huntington's disease. Oxford Monographs On Medical Genetics. Oxford: New York Oxford University Press (UK); 2002, volume 1
87. Reisine TD, Wastek GJ, Speth RC, et al. Alterations in the benzodiazepine receptor of Huntington's diseased human brain. Brain Res 1979;165:183-187 (Pubitemid 9126616)
88. Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust 1976;1:225-227
89. Stewart JT. Treatment of Huntington's disease with clonazepam. South Med J 1988;81:102
90. Farrell DF, Hofmann WW. A quantitative evaluation of the effect of diazepam in Huntington's chorea. Arch Phys Med Rehabil 1968;49:586-591
91. de Tommaso M, Difruscolo O, Sciruicchio V, et al. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol 2007;30:43-46 (Pubitemid 46204317)
92. Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006;67:1268-1271 (Pubitemid 44563842)
93. Ready RE, Mathews M, Leserman A, Paulsen JS. Patient and caregiver quality of life in Huntington's disease. Mov Disord 2008;23:721-726
94. Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 2001;71:310-314 (Pubitemid 32772526)
95. Bonelli RM. Mirtazapine in suicidal Huntington's disease. Ann Pharmacother 2003;37:452 (Pubitemid 36249652)
96. Patel SV, Tariot PN, Asnis J. L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease. Ann Clin Psychiatry 1996;8:23-26 (Pubitemid 26193734)
97. Ford MF. Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. Br J Psychiatry 1986;149:654-656 (Pubitemid 17170943)
98. Candelise L. Haloperidol, reserpine, l-dopa and amantidine in the treatment of Huntington chorea (author's transl). Riv Patol Nerv Ment 1976;96:54-62
99. Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 1999;19:101-103 (Pubitemid 29047341)
100. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics 2006;47:70-72 (Pubitemid 43017124)
101. Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther 2002;95:103-117 (Pubitemid 35232129)
102. Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 2006;18:553-554 (Pubitemid 44713898)
103. Kingma EM, van Duijn E, Timman R, et al. Behavioural problems in Huntington's disease using the problem behaviours assessment. Gen Hosp Psychiatry 2008;30:155-161 (Pubitemid 351255558)
104. Hamilton JM, Salmon DP, Corey-Bloom et al. Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry 2003;74:120-122 (Pubitemid 36069050)
105. Snowden JS, Craufurd D, Griffiths HL, Neary D. Awareness of involuntary movements in Huntington disease. Arch Neurol 1998;55:801-805 (Pubitemid 28265696)
106. Ho AK, Gilbert AS, Mason SL, et al. Goodman AO, Barker RA: Health-related quality of life in Huntington's disease: which factors matter most? Mov Disord 2008;24(4):572-576
107. Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995;81:811-823
108. Nellemann C, Abell K, Norremolle A, et al. Inhibition of Huntington synthesis by antisense oligodeoxynucleotides. Mol Cell Neurosci 2000;16:313-323 (Pubitemid 30808025)
109. Yen L, Strittmatter SM, Kalb RG. Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Ann Neurol 1999;46:366-373 (Pubitemid 29416274)
110. Dunah AW, Jeong H, Griffin A, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002;296:2238-2243 (Pubitemid 34680312)
111. Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000;97:6763-6768 (Pubitemid 30412788)
112. Jiang H, Poirier MA, Liang Y, et al. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol Dis 2006;23:543-551 (Pubitemid 44234090)
113. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413:739-743 (Pubitemid 33009952)
114. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003;23:9418-9427 (Pubitemid 37323042)
115. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003;100:2041-2046 (Pubitemid 36254570)
116. Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005;280:556-563 (Pubitemid 40165021)
117. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801 (Pubitemid 30469429)
118. Ryu JK, McLarnon JG. Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp Neurol 2006;198:552-557
119. Smith DL, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003;54:186-196 (Pubitemid 36909617)
120. Minocycline safety and tolerability in Huntington disease. Neurology 2004;63:547-549 (Pubitemid 39031391)
121. Bonelli RM, Heuberger C, Reisecker F. Minocycline for Huntington's disease: an open label study. Neurology 2003;60:883-884 (Pubitemid 36297384)
122. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord 2004;19:692-695 (Pubitemid 39173025)
123. Tanaka M, Machida Y, Niu S, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004;10:148-154 (Pubitemid 38524884)
124. Katsuno M, Adachi H, Sobue G. Sweet relief for Huntington disease. Nat Med 2004;10:123-124 (Pubitemid 38524873)
125. Tanaka K, Shouguchi-Miyata J, Miyamoto N, Ikeda JE. Novel nuclear shuttle proteins, HDBP1 and HDBP2, bind to neuronal cell-specific cis-regulatory element in the promoter for the human Huntington's disease gene. J Biol Chem 2004;279:7275-7286 (Pubitemid 38248877)
126. Valera AG, Diaz-Hernandez M, Hernandez F, et al. The ubiquitin-proteasome system in Huntington's disease. Neuroscientist 2005;11:583-594 (Pubitemid 41611870)
127. Ravikumar B, Rubinsztein DC. Role of autophagy in the clearance of mutant huntingtin: a step towards therapy? Mol Aspects Med 2006;27:520-527
128. Ayalon L, Doron R, Weiner I, Joel D. Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus. Exp Neurol 2004;186:46-58 (Pubitemid 38229904)
129. Lacey CJ, Boyes J, Gerlach O, et al. GABA(B) receptors at glutamatergic synapses in the rat striatum. Neuroscience 2005;136:1083-1095 (Pubitemid 41790522)
130. Calabresi P, Mercuri NB, Stefani A, Bernardi G. Synaptic and intrinsic control of membrane excitability of neostriatal neurons. I. An in vivo analysis. J Neurophysiol 1990;63:651-662
131. Centonze D, Rossi S, Prosperetti C, et al. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol Psychiatry 2005;57:1583-1589 (Pubitemid 40805389)
132. Dunnett SB, Rosser AE. Stem cell transplantation for Huntington's disease. Exp Neurol 2007;203:279-292 (Pubitemid 46149598)
133. Rosser AE, Barker RA, Harrower T, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 2002;73:678-685 (Pubitemid 35448852)
134. Kopyov OV, Jacques S, Lieberman A, et al. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 1998;149:97-108 (Pubitemid 28091019)
135. Bachoud-Levi A, Bourdet C, Brugieres P, et al. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol 2000;161:194-202 (Pubitemid 30136541)
136. Bachoud-Levi AC, Remy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000;356:1975-1979
137. Bachoud-Levi AC, Gaura V, Brugieres P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006;5:303-309
138. Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002;58:687-695 (Pubitemid 34211545)
139. Lescaudron L, Unni D, Dunbar GL. Autologous adult bone marrow stem cell transplantation in an animal model of huntington's disease: behavioral and morphological outcomes. Int J Neurosci 2003;113:945-956 (Pubitemid 36975650)
140. Ramaswamy S, Shannon KM, Kordower JH. Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant 2007;16:301-312 (Pubitemid 47300233)
141. Emerich DF, Cain CK, Greco C, et al. Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplant 1997;6:249-266 (Pubitemid 27225176)
142. Emerich DF, Winn SR, Hantraye PM, et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 1997;386:395-399 (Pubitemid 27154479)
143. Bloch J, Bachoud-Levi AC, Deglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004;15:968-975 (Pubitemid 39372573)
144. Hockly E, Cordery PM, Woodman B, et al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 2002;51:235-242 (Pubitemid 34111446)
145. van Dellen A, Hannan AJ. Genetic and environmental factors in the pathogenesis of Huntington's disease. Neurogenetics 2004;5:9-17 (Pubitemid 38297468)
146. van Praag H, Kempermann G, Gage FH. Neural consequences of environmental enrichment. Nat Rev Neurosci 2000;1:191-198
147. Lazic SE, Grote HE, Blakemore C, et al. Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci 2006;23:1829-1838
148. Spires TL, Grote HE, Varshney NK, et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 2004;24:2270-2276 (Pubitemid 38314558)
149. Young D, Lawlor PA, Leone P, et al. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat Med 1999;5:448-453 (Pubitemid 29180587)
150. Singhrao SK, Thomas P, Wood JD, et al. Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp Neurol 1998;150:213-222
151. Valenzuela MJ. Brain reserve and the prevention of dementia. Curr Opin Psychiatry 2008;21:296-302
152. Georgiou N, Bradshaw JL, Chiu E, et al. Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease. Mov Disord 1999;14:320-325 (Pubitemid 30011851)
153. Churchyard A. Lifestyle activity and age of onset in Huntington's disease. In: Huntington Disease Clinical Research Symposium. St Pete Beach, Florida, Huntington's Study Group: 2008
154. Vonsattel JP, Keller C, Pilar Amaya MD. Neuropathology of Huntington's disease. Handb Clin Neurol 2008;89:599-618
155. Hersch SM, Ferrante RJ. Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx 2004;1:298-306 (Pubitemid 46589358)
156. Ferrante RJ, Ryu H, Kubilus JK, et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci 2004;24:10335-10342 (Pubitemid 39552617)
157. Jones DE Jr, Cui DM, Miller DM. Expression of beta-galactosidase under the control of the human c-myc promoter in transgenic mice is inhibited by mithramycin. Oncogene 1995;10:2323-2330
158. Minamiyama M, Katsuno M, Adachi H, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004;13:1183-1192 (Pubitemid 38787000)
159. Hogarth P, Lovrecic L, Krainc D. Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Mov Disord 2007;22:1962-1964 (Pubitemid 350134213)
160. Keene CD, Rodrigues CM, Eich T, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci USA 2002;99:10671-10676 (Pubitemid 34907035)
161. Keene CD, Rodrigues CM, Eich T, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol 2001;171:351-360 (Pubitemid 32955297)
162. Wood NI, Morton AJ. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull 2003;61:375-383 (Pubitemid 36945468)
163. Aminoff MJ, Marshall J. Treatment of Huntington's chorea with lithium carbonate. A double-blind trial. Lancet 1974;1:107-109
164. Vestergaard P, Baastrup PC, Petersson H. Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial. Acta Psychiatr Scand 1977;56:183-188
165. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004;36:585-595 (Pubitemid 38715985)
166. Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002;8:143-149 (Pubitemid 34155125)
167. Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002;22:8942-8950 (Pubitemid 35379064)
168. Fox JH, Barber DS, Singh B, et al. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J Neurochem 2004;91:413-422 (Pubitemid 39363440)
169. Shults C, Steardo L, Barone P, et al. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology 1986;36:1099-1102 (Pubitemid 16038591)
170. Dubinsky R, Gray C. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov Disord 2006;21:530-533
171. Clifford JJ, Drago J, Natoli AL, et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 2002;109:81-88 (Pubitemid 34088148)
172. Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 2002;13:29-33 (Pubitemid 34102022)
173. Puri BK, Bydder GM, Counsell SJ, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002;13:123-126 (Pubitemid 34102040)
174. Puri BK, Bydder GM, Manku MS, et al. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease. J Int Med Res 2008;36:896-905
175. Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005;65:286-292 (Pubitemid 41022376)
176. Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington disease: The TREND-HD Study. Arch Neurol 2008;65:1582-1589
177. Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington's disease (HD). Mov Disord 1999;14:326-330 (Pubitemid 30011852)
178. Seppi K, Mueller J, Bodner T, et al. Riluzole in Huntington's disease (HD): an open label study with one year follow up. J Neurol 2001;248:866-869 (Pubitemid 32955670)
179. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003;61:1551-1556 (Pubitemid 37505578)
180. Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007;62:262-272 (Pubitemid 47525402)
181. Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996;11:273-277 (Pubitemid 26138825)
182. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404 (Pubitemid 32757583)
183. Klivenyi P, Ferrante RJ, Gardian G, et al. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem 2003;86:267-272 (Pubitemid 36753867)
184. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group. Neurology 1998;50:1366-1373 (Pubitemid 28240353)
185. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-215 (Pubitemid 351978110)
186. Available from: https://www.euro-hd.net
187. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-4397 (Pubitemid 30396603)
188. Dedeoglu A, Kubilus JK, Yang L, et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem 2003;85:1359-1367 (Pubitemid 36702548)
189. Verbessem P, Lemiere J, Eijnde BO, et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003;61:925-930 (Pubitemid 37248646)
190. Schilling G, Coonfield ML, Ross CA, Borchelt DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett 2001;315:149-153 (Pubitemid 33079072)
191. Smith KM, Matson S, Matson WR, et al. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta 2006;1762:616-626 (Pubitemid 43903119)
192. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002;22:1592-1599 (Pubitemid 35386278)
193. Van Raamsdonk JM, Pearson J, Bailey CD, et al. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 2005;95:210-220 (Pubitemid 41384439)
194. Andreassen OA, Ferrante RJ, Huang HM, et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann Neurol 2001;50:112-117
195. Van Raamsdonk JM, Pearson J, Rogers DA, et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 2005;196:266-272 (Pubitemid 41607814)
196. Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 2004;55:590-594 (Pubitemid 38391979)
197. Schilling G, Savonenko AV, Klevytska A, et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Hum Mol Genet 2004;13:1599-1610 (Pubitemid 39136716)
198. Hockly E, Tse J, Barker AL, et al. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiol Dis 2006;21:228-236 (Pubitemid 41817321)
199. Stack EC, Smith KM, Ryu H, et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 2006;1762:373-380 (Pubitemid 43172854)
200. Tabrizi SJ, Blamire AM, Manners DN, et al. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003;61:141-142 (Pubitemid 36818771)